SphynKx Therapeutics

SphynKx Therapeutics is a Dutch biotechnology company focused on developing first-in-class small molecule inhibitors of sphingosine-1-phosphate lyase (SPL) for the treatment of chronic kidney diseases. By targeting the S1P pathway, the company aims to address the underlying pathology of proteinuric kidney diseases, including rare conditions like Alport syndrome and more common forms like diabetic nephropathy. The company's lead program is currently in the pre-clinical stage, with a focus on restoring S1P signaling to protect podocytes and reduce fibrosis. SphynKx is headquartered in the Leiden BioScience Park and is backed by prominent European life science investors.